Navigation Links
Protein Sciences Expands License Agreement with UMN Pharma
Date:11/9/2010

ased in Meriden, Connecticut whose mission is to save lives and improve health by effectively responding to our changing world with innovative vaccines and biopharmaceuticals. PSC uses its platform production system to make novel human and veterinary prophylactic and therapeutic vaccines and diagnostics. PSC's platform technology is covered by broad patents that include its proprietary expresSF+® cell insect line that is uses to make all of its and its GeneXpress® customers' products.

PSC's lead product is FluBlok, a seasonal recombinant trivalent influenza vaccine consisting of influenza hemagglutinin (HA) proteins.  FluBlok is manufactured using cell culture instead of eggs, is highly purified and therefore does not require the use of thimerosal or antibiotics, and is low in endotoxins.  PSC filed a Biologics License Application for FluBlok with the FDA in April 2008 that was accepted in June 2008 and received "Fast Track" designation in July 2008.  PSC anticipates that FluBlok may receive FDA approval within a few months.  In 2009 the Company was awarded a $34.5 million contract by the Biomedical Advanced Research and Development Authority, a division of the Department of Health and Human Services, to further develop a recombinant technology for the production of recombinant influenza vaccines for pandemic preparedness. This contract could be extended up to a total of five years with a total value of approximately $147 million.


'/>"/>
SOURCE Protein Sciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
2. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
3. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
4. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
5. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
8. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
9. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
10. Neptune Industries Reports Favorable Phase II Trial Results on Ento- Protein(TM)
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Ortho Clinical Diagnostics (OCD) today announced that ... and Communications Officer, effective immediately. As the newest member ... the company,s worldwide corporate brand and communication strategies as ... company by adding sites in countries outside the U.S. ... Dr. Martin Madaus . Since becoming ...
(Date:8/3/2015)... Global physiotherapy equipments ... 24.7 billion by 2022, according to a new ... of neurological and musculoskeletal disorders are expected to ... period. The presence of efficient and effective therapies ... technologies coupled with implementation of favorable government policies ...
(Date:8/3/2015)... ANGELES, Aug. 3, 2015  CytRx Corporation (NASDAQ: ... in oncology, today reported financial results for the three ... overview of recent accomplishments and upcoming milestones for its ... 2015 has been very productive for CytRx. Enrollment in ... aldoxorubicin in soft tissue sarcoma (STS) continues on track ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14
... Dec. 4 Long-term data published in,EuroIntervention showed ... (MVA),after repair with the MitraClip(R) system to correct ... mitral stenosis. Additionally,with two years of follow-up, none ... surgery for mitral stenosis. At 12 months no,important ...
... newly diagnosed patients with a life-threatening type of leukemia to be ... , - Exjade results at ASH to show benefits ... damage key organs , , - ... to report on optimal post-surgery treatment strategy, Femara vs. tamoxifen , ...
Cached Medicine Technology:Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22
(Date:8/3/2015)... Irvine, CA (PRWEB) , ... August 03, 2015 ... ... for Hispanic Health notes that while an overwhelming number of Hispanics believe ... health. , The overwhelming 70 percent of participants queried said making diet changes ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... of its industry-defining contract lifecycle management solution, as well as announced the date ... increase the speed and ease of contract management tasks as well as enhancements ...
(Date:8/3/2015)... OR (PRWEB) , ... August 03, 2015 , ... ... California’s Modoc National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its ... California’s largest untapped ground water aquifers, whose main outflow is at Ahjumawi Lava ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science ... 31. , The acquisition includes all of IBAM NA’s cyclotron sites and research ... both, a robust regionally located business, as well as a large manufacturing hub in ...
(Date:8/3/2015)... ... , ... Foot and Ankle Specialists of the Mid-Atlantic (FASMA) is ... practice in the Mid-Atlantic region – and the second largest in the United States ... , Dr. Hetal Kathrotiya-Mago is a Maryland native. She grew up in Laurel, Maryland. ...
Breaking Medicine News(10 mins):Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Novatus Unveils Milestone Software Release 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4
... less likely, women more, to develop the disorder, study finds, ... a neurological disorder characterized by a strong urge to move ... than others, a new U.S. study has found. , Researchers ... About 12 percent of those who were black, compared with ...
... National Laboratory are collaborating on a study to determine ... the space shuttle can be used to predict tissue ... therapy. The study is examining the utility of ... from the study are being displayed during the American ...
... currently under development by the University of Pittsburgh School ... after radiation exposure, according to a study by Pitt ... p.m. today during the American Society for Radiation Oncology ... is a free-radical scavenger targeted to the mitochondria, the ...
... in packaging, paper and exposures were evident in most ... -- Chemicals used in food packaging, paper and textile ... researchers have found. , Previous studies have found that ... most people. In this new study, a team at ...
... Skin Cell is the Star Avatar at KidsSkinHealth.org , SCHAUMBURG, ... by dermatologists lets kids learn how to practice ... , greasy hair, a poison ivy rash ... Cell,s Life," is just one of the many features on the American ...
... 2 Blue Cross Blue Shield of Michigan and ... innovative oncology treatment initiative aimed at enhancing the quality ... , OPR, a statewide physician organization comprised ... working with oncology leaders from across Michigan, as well ...
Cached Medicine News:Health News:Restless Legs May Vary by Race and Gender 2Health News:Adapting space-industry technology to treat breast cancer 2Health News:Adapting space-industry technology to treat breast cancer 3Health News:Household Chemicals May Affect Cholesterol Levels 2Health News:Dermatologists Launch New Web Site and Game to Teach Kids about Healthy Skin, Hair and Nail Habits 2Health News:Dermatologists Launch New Web Site and Game to Teach Kids about Healthy Skin, Hair and Nail Habits 3Health News:Blue Cross Blue Shield of Michigan and Michigan Oncologists Launch Statewide Initiative to Create Cancer Guidelines 2Health News:Blue Cross Blue Shield of Michigan and Michigan Oncologists Launch Statewide Initiative to Create Cancer Guidelines 3
For surgical treatment, repair and irrigation of the nasolacrimal system. Stainless steel probes, 20G x 1 3/4in (.90 x 45cm) Silicone rod, length 13 3/4in (40cm), Diameter.032in (.80mm)...
For surgical treatment, repair and irrigation of the nasolacrimal system. Stainless steel probes, 23G x4 1/2in (.60mm x 11cm) Silicone tubing, length 14in (35cm), ID: .012in (.30mm) OD: .025in (.60mm...
IOL choppers for positioning intraocular lenses. Blunt tip avoids damage to intraocular lenses. For .20mm diameter holes and larger....
...
Medicine Products: